文献速递肿瘤 PET/CT骨显像与常规 SPECT

[68Ga]Ga-FAPI-04 PET/CT或可预测类风湿关节炎早期治疗反应

[68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis.
PubMed 文献 · EJNMMI Res · 2024-01-04

前瞻性队列研究纳入19例类风湿关节炎患者,探讨基线[68Ga]Ga-FAPI-04 PET/CT能否预测3个月随访时的治疗反应。结果显示,按CDAI和SDAI反应标准,反应者的FAPI-04及FDG PET/CT总滑膜炎摄取和代谢性滑膜炎体积均显著高于非反应者,基线FAPI PET/CT参数高于截断值可区分反应者与非反应者。

要点

  • 按CDAI和SDAI标准,3个月随访反应者的FAPI-04与FDG PET/CT总滑膜炎摄取及代谢性滑膜炎体积均显著高于非反应者。
  • FAPI-04和FDG PET/CT的PET关节计数在CDAI反应者中显著高于非反应者。
  • 基线FAPI PET/CT的PJC、TSU、MSV高于截断值可区分3个月随访的CDAI和SDAI反应者与非反应者。

核心结论

  • 基线[68Ga]Ga-FAPI-04摄取在早期反应者中显著高于非反应者。

研究设计与样本

  • 前瞻性队列研究最终纳入19例确诊类风湿关节炎的患者。
  • 试验注册号ClinicalTrials NCT04514614,注册日期2020年8月13日。

主要发现

  • 按CDAI和SDAI反应标准,3个月随访时反应者的[68Ga]Ga-FAPI-04和[18F]FDG PET/CT总滑膜炎摄取及代谢性滑膜炎体积均显著高于非反应者(P < 0.05)。
  • CDAI反应者的FAPI-04 PET/CT PET关节计数显著高于非反应者(P = 0.016),FDG PET/CT PET关节计数亦显著高于非反应者(P = 0.045)。
  • 基线疾病活动度临床特征在反应者与非反应者间无显著差异,除外CRP(CDAI标准P = 0.035,SDAI标准P = 0.033)。
  • 基线[68Ga]Ga-FAPI-04 PET/CT的PJC、TSU和MSV高于截断值可成功区分3个月随访的CDAI和SDAI反应者与非反应者。

关键数值与推荐

  • 采用CDAI和SDAI反应标准在3个月随访时判定反应者与非反应者。
  • 基线FAPI PET/CT的PJC、TSU、MSV高于截断值可区分CDAI和SDAI反应者与非反应者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The identification of biomarkers predicting the treatment response of rheumatoid arthritis (RA) is important. [68 Ga]Ga-FAPI-04 showed markedly increased uptake in the joints of patients with RA. The purpose of this study is to investigate whether [68 Ga]Ga-FAPI-04 PET/CT can be a predictor of treatment response in RA. RESULTS: Nineteen patients diagnosed with RA in the prospective cohort study were finally enrolled. Both total synovitis uptake (TSU) and metabolic synovitis volume (MSV) in [68 Ga]Ga-FAPI-04 and [18F]FDG PET/CT of the responders were significantly higher than those in non-responders according to Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) response criteria at 3-months' follow-up (P < 0.05). The PET joint count (PJC) detected in [68 Ga]Ga-FAPI-04 and [18F]FDG PET/CT were also significantly higher in CDAI responders than non-responders (P = 0.016 and 0.045, respectively). The clinical characteristics of disease activity at baseline did not show significant difference between the responders and non-responders, except CRP (P = 0.035 and 0.033 in CDAI and SDAI response criteria, respectively). The baseline PJCFAPI, TSUFAPI and MSVFAPI > cutoff values in [68 Ga]Ga-FAPI-04 PET/CT successfully discriminated CDAI and SDAI responders and non-responders at 3-months' follow-up. CONCLUSION: [68 Ga]Ga-FAPI-04 uptake at baseline were significantly higher in early responders than those in non-responders. Trial registration ClinicalTrials. NCT04514614. Registered 13 August 2020, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000A4PN&selectaction=Edit&uid=U0001JRW&ts=2&cx=-x9t7cp.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Pan Q, Yang H, Zhou Z, et al. [68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis. EJNMMI Res. 2024. PMID: 38175339. doi:10.1186/s13550-023-01064-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。